cases resembled acute myelogenous leukemia; and one case presented with findings of a combined myelodysplastic syndrome/myeloproliferative neoplasm. best treatments for etv6-acsl6-related disease are unclear. patients with the polycythemia vera form of the disease have been treated by reducing the circulating red blood cell load by phlebotomy or suppressing red blood cell formation using hydroxyurea. individual case studies report that etv6-acsl6-associated disease is insensitive to tyrosine kinase inhibitors. best treatment currently available, therefore, may involve chemotherapy and bone marrow transplantion. eosinophilia associated with other hematological diseases main article: eosinophilia main article: hypereosinophilia lymphocyte-variant hypereosinophilia is a rare disease in which eosinophilia is caused by aberrant t cell lymphocytes which secrete cytokines (e.g. interleukin-5) that stimulate the proliferation of eosinophil precursor cells. the disease, which occasionally proceeds to a malignant lymphocytic phase, clearly reflects a clonal disturbance in lymphocytes, not eosinophils, and therefore is not a clonal hypereosinophilia. similar non-clonal eosinophilia due to eosinophil precursor cell stimulation by clonal malignant cells is sometimes seen in cases of hodgkin disease, b-cell lymphoma, t-cell lymphomas, t cell leukemias, and langerhans cell histiocytosis. other hematological diseases are associated with eosinophilia but regarded as clonal eosinophilia associated with a more important clonal malignancy in another cell type. for example, eosinophilia occurs in 20% to 30% of patients with systemic mastocytosis. also referred to as sm-eo (systemic mastocytosis with eosinophilia) or sm-sel (systemic mastocytosis with chronic eosinophilic leukemia), this disease's clonal eosinophils bear the same driving mutation, d816v in the kit gene, as the clonal mast cells.